



Unsupervised home spirometry *versus* supervised clinic spirometry for respiratory disease: a systematic methodology review and meta-analysis

Rohan Anand ¹, Rebecca McLeese ¹, John Busby ², Jonathan Stewart ¹, Mike Clarke ², William D-C. Man ^{3,4,5} and Judy Bradley ¹

¹Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. ²Centre for Public Health, Queen's University Belfast, Belfast, UK. ³Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK. ⁴Faculty of Life Sciences and Medicine, King's College London, London, UK. ⁵National Heart and Lung Institute, Imperial College London, London, UK.

Corresponding author: Judy Bradley (judy.bradley@qub.ac.uk)



Shareable abstract (@ERSpublications)

Unsupervised spirometry for assessing patients with respiratory conditions requires caution as it underestimates spirometry in clinic; clinicians must consider the potential for differences. Home and clinic spirometry measurements are not interchangeable. <https://bit.ly/42pqwG7>

Cite this article as: Anand R, McLeese R, Busby J, *et al.* Unsupervised home spirometry *versus* supervised clinic spirometry for respiratory disease: a systematic methodology review and meta-analysis. *Eur Respir Rev* 2023; 32: 220248 [DOI: 10.1183/16000617.0248-2022].

Copyright ©The authors 2023

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

Received: 16 Dec 2022
Accepted: 31 May 2023

Abstract

Background: The number of patients completing unsupervised home spirometry has recently increased due to more widely available portable technology and the COVID-19 pandemic, despite a lack of solid evidence to support it. This systematic methodology review and meta-analysis explores quantitative differences in unsupervised spirometry compared with spirometry completed under professional supervision.

Methods: We searched four databases to find studies that directly compared unsupervised home spirometry with supervised clinic spirometry using a quantitative comparison (*e.g.* Bland–Altman). There were no restrictions on clinical condition. The primary outcome was measurement differences in common lung function parameters (forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC)), which were pooled to calculate overall mean differences with associated limits of agreement (LoA) and confidence intervals (CI). We used the I² statistic to assess heterogeneity, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool to assess risk of bias and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence certainty for the meta-analyses. The review has been registered with PROSPERO (CRD42021272816).

Results: 3607 records were identified and screened, with 155 full texts assessed for eligibility. We included 28 studies that quantitatively compared spirometry measurements, 17 of which reported a Bland–Altman analysis for FEV₁ and FVC. Overall, unsupervised spirometry produced lower values than supervised spirometry for both FEV₁ with wide variability (mean difference –107 mL; LoA= –509, 296; I²=95.8%; p<0.001; very low certainty) and FVC (mean difference –184 mL, LoA= –1028, 660; I²=96%; p<0.001; very low certainty).

Conclusions: Analysis under the conditions of the included studies indicated that unsupervised spirometry is not interchangeable with supervised spirometry for individual patients owing to variability and underestimation.

Introduction

Traditionally, patients perform spirometry in a clinic setting supervised by a trained professional under standardised conditions [1, 2]. Spirometry is used extensively for diagnosis and for monitoring patients with respiratory conditions between clinic visits, with measurements used to assess disease severity and control [3–5]. In clinical research, lung function is an important outcome measure to assess intervention



efficacy [6–8] and is a constituent of clinical trial core outcome sets for chronic obstructive pulmonary disease (COPD) [9], bronchiectasis [10] and pulmonary infections [11].

The Association for Respiratory Technology & Physiology (ARTP) advise that spirometry should be conducted under the supervision of professionals who have completed comprehensive training [12]. However, accelerated by the COVID-19 pandemic and with increased pressure on healthcare systems, routine respiratory services and clinical trials have now adopted unsupervised remote spirometry mainly for the monitoring of patients [13–15]. These portable spirometers have been advocated by healthcare providers [16–18] and have been positively received by patients [19–22], despite no conclusive evidence that unsupervised and supervised spirometry measurements are equivalent to those obtained in clinic. It is crucial to know whether unsupervised assessments are valid and reliable before mass uptake. However, if feasible, remote unsupervised spirometry could support virtual healthcare services in routine care and enable more pragmatic trial designs [23], such as the development and scaling of decentralised clinical trials [24].

The primary objective of the review was to determine if spirometry measurements completed by patients unsupervised at home are different to those obtained under the supervision of a trained professional. It assessed differences between two quantitative methods of measurement used as part of respiratory care in clinical research and clinical practice, rather than assessing the effects of the care itself [25]. Secondary objectives were to explore adherence to unsupervised spirometry, patient satisfaction/acceptability, technical issues, quality of spirometry data, adverse events and costs.

Methods

The analysis explicitly focused on measurement differences between two methods, unsupervised and supervised spirometry (definitions in supplementary material), and so was completed as a test accuracy review. The protocol for this review was registered prospectively on PROSPERO (ID: CRD42021272816) [26], providing full details on methods. Variations between the protocol and review are described in the supplementary material.

Criteria for study inclusion

Studies were included if they compared values obtained from unsupervised spirometry to those obtained from supervised spirometry. These could be from using the same or different spirometers. There was no maximum time difference between measurements. Eligible study designs included cross-sectional, longitudinal, randomised or non-randomised controlled or crossover studies in which participants performed both forms of spirometry. Sub-studies embedded within another study were also eligible. There were no restrictions on the type of publications included but they had to be complete datasets, *i.e.* ongoing studies with preliminary data were not included.

Criteria for study exclusion

We excluded studies in which there was no comparison group and if the publication was not in English.

Population, intervention, comparator, outcomes

The population, intervention, comparator, outcomes (PICO) terms are detailed fully in the published protocol [26]. In brief, there were no restrictions based on age, disease type or clinical condition. We deemed the intervention group for this review as unsupervised spirometry in the complete absence of a clinician or other professional support. The comparator group was supervised spirometry use in the presence of a clinician or other relevant professional and could include assistance *via* telephone or video link. The primary outcome was measurement of lung function in the intervention and comparator groups, primarily assessed by mean differences in forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC), forced expiratory flow at 25–75% of FVC (FEF_{25–75%}) and peak expiratory flow (PEF) measurements. Secondary outcomes included exploring adherence, quality criteria, cost, participant satisfaction/acceptability, technical issues and adverse events.

Search strategy

We conducted searches for relevant studies from database inception to 15 July 2021 in the electronic databases MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and a grey literature search on Open Access Theses and Dissertations (OATD) (no eligible studies were retrieved from the grey literature search). We also checked the reference lists of eligible studies or related reviews for additional studies and did forward citation screening of eligible studies. The full search strategy including Medical Subject Headings (MeSH) terms was validated by a medical librarian. All database searches were

completed by one author. Additional search strategy information, including the specific search strategy used for each source, can be found in the supplementary material.

Selection of studies

Search results were imported into the systematic review manager software, Covidence (www.covidence.org). This platform was used for abstract screening, full-text screening and data extraction of eligible studies. Any two authors independently screened titles and abstracts according to the eligibility criteria. Studies deemed potentially eligible had their full texts independently screened by any two authors. Any disagreements or uncertainties were resolved through discussion and, if needed, the involvement of other authors.

Data extraction

Data were extracted independently for each included study by two authors using a customised data extraction form developed in Covidence. Information extracted included the type of study, eligibility criteria, participant characteristics and details of the spirometers with associated measurements (mean differences, standard deviations and correlations). Outcomes of interest were FEV₁, FVC, FEF_{25–75%} and PEF. If any of the required data were not available or insufficient, they were requested from the corresponding author of the study.

Data synthesis and statistical methods

Mean differences and standard deviations were extracted from studies which reported Bland–Altman analyses. Standard deviations were inferred from confidence intervals and limits of agreement (LoA) when they were not reported directly. When no relevant data were reported we imputed the median standard deviation from all other studies reporting that outcome [27]. Meta-analyses were conducted using DerSimonian–Laird random-effects models and the statistical heterogeneity evaluated using the I² statistic [28] and interpreted using the thresholds defined by the Cochrane Handbook [29]. We calculated pooled mean differences with associated 95% confidence intervals, which represent uncertainty around the mean bias estimate. However, to increase the clinical utility of our results, we also calculated pooled LoA around the mean differences, which reflects an interval within which 95% of the differences would lie for a given measurement. Pooled standard deviations were calculated according to the methods outlined in the Cochrane Handbook [29]. Supervised measurements were subtracted from unsupervised, so a negative mean difference indicated that unsupervised spirometry measurements were lower than supervised measurements. The percentage of results that would be expected to have a difference >200 mL was also calculated.

We grouped diseases as obstructive lung disease (COPD and asthma), interstitial lung disease (idiopathic pulmonary fibrosis, interstitial lung disease and pulmonary sarcoidosis), suppurative lung disease (cystic fibrosis) and transplant (lung transplantation and haematopoietic cell transplantation). We reported results for different clinical groups separately if they were presented within the same study and could be separated [30]. Additionally, we performed prespecified subgroup analysis to investigate heterogeneity by patient age (children *versus* adult) and risk of bias (low risk of bias *versus* high risk of bias). We used the baseline measurement for studies that conducted spirometry at multiple timepoints. Pearson and Spearman correlation coefficients measuring the association between unsupervised and supervised spirometry were extracted and pooled based on the Fisher transformation. Data relating to secondary outcomes are presented descriptively. We collated data if it was documented that spirometry had been conducted according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines [1]. Two-tailed tests were used throughout and the threshold for statistical significance was set to 0.05. All analyses were conducted using STATA version 16 (StataCorp, College Station, TX, USA).

Risk of bias assessment

We assessed risk of bias of included studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, which is the most appropriate method to assess risk of bias in this type of review [31]. It assesses risk across four key domains (D1–D4): patient selection, index test (unsupervised spirometry), reference standard (supervised spirometry) and patient flow/timing. A study was determined to be at an overall risk of bias if one or more domains were judged to be at high or unclear risk of bias. A study was determined to be at an overall low risk if all the following were applied: adequate quality criteria for both the supervised and unsupervised spirometry measures, appropriate patient selection and appropriate time intervals between the two measurements, as per QUADAS guidance. A tailored extraction form for this review was piloted and used (available in the supplementary material). Two review authors independently used the tool to assess eligible studies. Any disagreements or uncertainties were resolved through discussion and, if needed, the involvement of other authors.

Quality of evidence

We assessed overall certainty of the evidence for the primary outcome using the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach specific to diagnostic test accuracy [32, 33].

Results

Literature search

Following database searches, reference list screening and citation screening, 3933 records were identified (figure 1). Following removal of duplicates, 3607 records had titles and abstracts screened and 155 full texts were checked for eligibility. After full-text screening, 28 studies were determined to meet all eligibility criteria and included in the review.

Study characteristics

Characteristics of included trials are summarised in table 1. This review included 25 prospective studies and three retrospective studies. Included studies totalled 4560 patients, ranging from nine to 2161. Studies included four distinct patient cohorts: interstitial lung disease (n=10) [35, 41, 43–48, 54, 58], transplant (n=8) [36, 38, 42, 49, 51, 56, 57, 59], obstructive airways disease (n=5) [19, 39, 40, 50, 53] and suppurative lung disease (n=5) [30, 34, 37, 52, 55]. In all studies, unsupervised spirometry was completed using a portable handheld spirometer, with a variety of device manufacturers and models used. Eight out of 28 studies [19, 30, 34, 38, 42, 53, 56, 58] explicitly stated that the quality criteria for both unsupervised and supervised measurements was according to ATS/ERS criteria. Five out of 28 studies [19, 34, 53, 57, 58] used the same spirometer for both the unsupervised and supervised measurements.

Risk of bias

For the QUADAS risk of bias assessment (supplementary material), five studies were assessed as having an overall low risk of bias across all domains. 23 studies were assessed as at risk of bias due to one or more domains being at high or unclear risk, as per reasons described within the Methods section.




FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

TABLE 1 Characteristics of included studies

Study	Study design	Country	Mean age (years)	Grouping (disease)	Patients (n)	Device used for unsupervised spirometry	Outcomes reported
BELL 2022 [34]	Longitudinal	Australia	37	Suppurative lung disease (CF)	74	Air Next (NuvoAir)	FEV ₁ , FVC
BROOS 2018 [35]	Longitudinal	The Netherlands	43	Interstitial lung disease (pulmonary sarcoidosis)	21	MicroDiary (CareFusion)	FVC
CHENG 2016 [36]	Longitudinal	USA	51 [#]	Transplant (haematopoietic cell transplantation)	571	KoKo Peak Pro6 (Ferraris Respiratory) or PiKo-6 (Pulmonary Data Services)	FEV ₁ , FVC
EDMONDSON 2020 [37]	Single day cross-over	UK and Canada	10 [#]	Suppurative lung disease (CF)	67	Lung Monitor BT SMART (Vitalograph)	FEV ₁
FINKELSTEIN 1993 [38]	Longitudinal	USA	50	Transplant (lung transplant)	18	Advanced Medical Systems Inc.	FEV ₁ , FVC
FINKELSTEIN 2000 [19]	Longitudinal	USA	42	Obstructive airways disease (Asthma)	32	V2120 (Vitalograph)	FEV ₁ , FVC, FEF _{25-75%} , PEF
GERZON 2020 [¶] [30]	Single day cross-over	Netherlands	CF 9 Asthma 10	Suppurative lung disease (CF) and obstructive airways disease (asthma)	CF 36 Asthma 81	AM2+ (CareFusion)	FEV ₁
HUANG 2021 [39]	Longitudinal	UK	41	Obstructive airways disease (asthma)	12	mSpirometer (Cohero Health)	FEV ₁
KERWIN 2019 [¶] [40]	Longitudinal	USA	N/A	Obstructive airways disease (asthma)	21	AM3 (eResearch Technology)	FEV ₁
KHAN 2022 [41]	Longitudinal	UK	70	Interstitial lung disease (interstitial lung disease)	82	Spirobank Smart (MIR)	FEV ₁
LINDGREN 1997 [42]	Longitudinal	USA	48	Transplant (lung transplant)	77	PFM-H100 (Telemedical Inc.)	FEV ₁ , FVC
MARCOUX 2019 [43]	Longitudinal	Canada	73	Interstitial lung disease (idiopathic pulmonary fibrosis)	20	Spirometer (PMD Healthcare)	FVC
MOOR 2018 [44]	Longitudinal	The Netherlands	71	Interstitial lung disease (idiopathic pulmonary fibrosis)	10	Spirobank Smart (MIR)	FEV ₁ , FVC
MOOR 2019 [45]	Longitudinal	The Netherlands	53 [#]	Interstitial lung disease (pulmonary sarcoidosis)	10	Spirobank Smart (MIR)	FEV ₁ , FVC
MOOR 2020a [46]	Longitudinal	The Netherlands	70 [#]	Interstitial lung disease (idiopathic pulmonary fibrosis)	46	Spirobank Smart (MIR)	FVC
MOOR 2020b [47]	Longitudinal	The Netherlands	68 [#]	Interstitial lung disease (interstitial lung disease)	50	Spirobank Smart (MIR)	FVC
MOOR 2021 [48]	Longitudinal	Netherlands	60	Interstitial lung disease (interstitial lung disease)	10	Spirobank Smart (MIR)	FVC
MORLION 2002 [49]	Longitudinal	Belgium	33	Transplant (lung transplant)	22	Microloop II (MicroMedical)	FEV ₁ , FEF _{25-75%}
MORTIMER 2003 [¶] [50]	Longitudinal	USA	9	Obstructive airways disease (asthma)	92	EasyOne (NDD Medical)	FEV ₁ , FVC, FEF _{25-75%} , PEF
ODISHO 2021 [51]	Longitudinal	USA	N/A	Transplant (lung transplant)	311	Spirometer (Not reported)	FEV ₁
PAYNTER 2021 [52]	Longitudinal	USA	27	Suppurative lung disease (CF)	135	AM2+ (ERT Inc.)	FEV ₁
RODRIGUEZ-ROISIN 2016 [53]	Longitudinal	Global	64	Obstructive airways disease (COPD)	2488	EasyOne (NDD Medical)	FEV ₁
RUSSELL 2016 [54]	Longitudinal	UK	67	Interstitial lung disease (idiopathic pulmonary fibrosis)	50	Microspirometer (CareFusion)	FEV ₁ , FVC
SHAKKOTTAI 2018 [55]	Longitudinal	USA	16	Suppurative lung disease (CF)	39	Spiro PD (PMD Healthcare)	FEV ₁
SHESHADRI 2020 [56]	Longitudinal	USA	55 [#]	Transplant (haematopoietic cell transplantation)	82	GoSpiro (Monitored Therapeutics)	FEV ₁ , FVC

Continued

TABLE 1 Continued

Study	Study design	Country	Mean age (years)	Grouping (disease)	Patients (n)	Device used for unsupervised spirometry	Outcomes reported
TURNER 2021 [57]	Longitudinal	USA	59 [#]	Transplant (haematopoietic cell transplantation)	46	GoSpiro (Monitored Therapeutics)	FEV ₁ , FVC
VEIT 2020 [58]	Longitudinal	Germany	63	Interstitial lung disease (interstitial lung disease)	47	mySpirosense (PARI)	FVC
WIJBENGA 2020 [59]	Longitudinal	The Netherlands	67	Transplant (lung transplant)	10	Spirobank Smart (MIR)	FEV ₁ , FVC

Disease was classed as the predominant condition in the study population. CF: cystic fibrosis; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF_{25–75%}: forced expiratory flow at 25–75% of the FVC; PEF: peak expiratory flow; COPD: chronic obstructive pulmonary disease. [#]: median age reported; [†]: studies in children (KERWIN *et al.* [40] reports outcomes of a subanalysis of 12–17-year-olds).

FEV₁

For the primary outcome of FEV₁, 17 studies (4517 patients; 9855 data comparison points) reported Bland–Altman data for FEV₁. Pooled analysis showed the overall mean difference for FEV₁ between unsupervised and supervised spirometry was –106 mL lower when unsupervised (LoA= –509 mL, 296 mL; I²=95.8%; p<0.001; figure 2). Six studies included patients with obstructive lung disease with a mean difference of –64 mL (LoA= –378 mL, 250 mL; I²=96.7%). Two studies included patients with interstitial lung disease with a mean difference of –187 mL (LoA= –721 mL, 348 mL; I²=0.0%). Three studies included patients with suppurative lung disease with a mean difference of –83 mL (LoA= –845 mL, 680 mL; I²=95.6%). Seven studies included transplant patients with a mean difference of –149 mL (LoA= –818 mL, 520 mL; I²=78.4%).

A subgroup analysis of four studies that had a low risk of bias found a mean difference of –103 mL (LoA= –444 mL, 238 mL; I²=96.2%; table 2) between unsupervised and supervised measurements. The 14 studies that were at risk of bias had a mean difference of –115 mL (LoA= –705 mL, 475 mL; I²=95.9%). Subgroup analysis for studies that compared unsupervised and supervised measurements within the same day and studies with adults and children are shown in table 2. The forest plots for these analyses are in the supplementary material. There was noticeable asymmetry with funnel plot estimates for FEV₁ (supplementary material). In addition, 12 studies reported correlation values for FEV₁ with an overall median of 0.949 (IQR 0.855, 0.982; supplementary material).

FVC

17 studies (n=1307 patients; 1926 data comparison points) reported Bland–Altman data for FVC, with pooled analysis showing the overall mean difference between unsupervised and supervised spirometry was –184 mL lower when unsupervised (LoA= –1028 mL, 660 mL; I²=96%; p<0.001; figure 3). Two studies included patients with obstructive lung disease with a mean difference of 2 mL (LoA= –328 mL, 333 mL; I²=77.8%). Eight studies included patients with interstitial lung disease with a mean difference of –199 mL (LoA= –753 mL, 354 mL; I²=72.4%). One study included patients with suppurative lung disease with a mean difference of –5 mL (LoA= –267 mL, 277 mL). Six studies included transplant patients with a mean difference of –260 mL (LoA= –1379 mL, 859 mL; I²=90.8%).

A subgroup analysis of four studies that had a low risk of bias found a mean difference of –118 mL (LoA= –886 mL, 650 mL; I²=88.5%; table 2) between unsupervised and supervised measurements. The 13 studies that were at risk of bias had a mean difference of –207 mL (LoA= –1098 mL, 684 mL; I²=96.6%). Subgroup analysis for studies that compared unsupervised and supervised measurements within the same day and studies with adults and children are shown in table 2. The forest plots for these analyses are in the supplementary material. There was noticeable asymmetry with funnel plot estimates (supplementary material). In addition, 14 studies reported correlation values for FVC with an overall median of 0.967 (IQR 0.940, 0.976; supplementary material).

FEF_{25–75%} and PEF

Three studies reported FEF_{25–75%} (146 patients; 899 data comparison points) with an overall mean difference of –19 mL·s^{–1} when unsupervised (LoA= –497 mL·s^{–1}, 458 mL·s^{–1}; I²=99.7%). Two studies




FIGURE 2 Meta-analysis of Bland-Altman for forced expiratory volume in 1 s (in mL) according to type of disease. LoA: limits of agreement. #: GERZON *et al.* [30] reported values for asthma (2020a) and cystic fibrosis patients (2020b) separately and these were treated as two separate studies.

reported PEF (124 patients; 400 data comparison points) with an overall mean difference of $-92 \text{ mL}\cdot\text{s}^{-1}$ (LoA= $-498 \text{ mL}\cdot\text{s}^{-1}$, $314 \text{ mL}\cdot\text{s}^{-1}$; $I^2=0.0\%$). The forest plots for these analyses are in the supplementary material.

Secondary outcomes

The secondary outcomes of adherence, patient satisfaction/acceptability, technical issues, quality of spirometry data, adverse events and costs are summarised in the supplementary material.

GRADE

For the primary outcome, the certainty of the evidence was deemed very low for all four measures (supplementary material).

Discussion

Despite the rationale for why unsupervised spirometry might be useful for monitoring respiratory patients with respiratory conditions [17, 18], we found that on average unsupervised spirometry measurements were lower (FEV₁ and FVC) than supervised measurements, with wide variability. This is contrary to the interpretations in some studies that have stated that unsupervised spirometry values are acceptable. However, we found that the large variation has been obscured in many cases because of a focus on the mean differences with confidence intervals and correlations. We assert this is not the most appropriate

TABLE 2 Summary of findings and subgroup analyses

Outcomes and subgroups	Participants (n)	Studies (n)	Mean difference (unsupervised–supervised) [#]	LoA	95% CI	I ² (%)	Anticipated impact (%) [¶]
FEV₁ overall	4517	17	–106 mL	–509, 296	–129, –84	95.8	38.9
Low risk of bias	2679	4	–103 mL	–444, 238	–160, –46	96.2	38.6
At risk of bias	1178	14	–115 mL	–705, 475	–154, –75	95.9	39.9
Same day measurements	235	5	–65 mL	–421, 292	–129, –1	95.4	35
Non-same day measurements	3520	11	–144 mL	–561, 272	–184, –105	95.3	43.8
Adults	3627	14	–103 mL	–517, 311	–134, –73	93.6	38.6
Children	230	4	–132 mL	–410, 146	–222, –42	98.2	42.1
FVC overall	1307	17	–184 mL	–1028, 660	–253, –114	96	66.9
Low risk of bias	238	4	–118 mL	–886, 650	–201, –35	88.5	65.2
At risk of bias	1069	13	–207 mL	–1098, 684	–300, –114	96.6	67.7
Same day measurements	106	2	–14 mL	–287, 260	–42, 15	0	63.9
Non-same day measurements	1099	13	–228 mL	–1239, 783	–285, –171	85.3	68.4
Adults	1215	16	–198 mL	–1162, 766	–262, –134	92.5	67.7
FEF_{25–75%}	146/899	3	–19 mL·s ^{–1}	–497, 458	–329, 291	99.7	41.3
PEF	124/400	2	–92 mL·s ^{–1}	–498, 314	–110, –74	0	38.1

The standard deviation was imputed for five studies so mean differences could be calculated after efforts were made to obtain data from authors [30, 37, 38, 40, 49]. LoA: limits of agreement; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF_{25–75%}: forced expiratory flow at 25–75% of the FVC; PEF: peak expiratory flow. [#]: a negative mean difference indicates unsupervised spirometry is lower. [¶]: percentage of results that would probably have a difference >200 mL.

analysis to compare agreement by two methods of measurement as demonstrated by BLAND and ALTMAN [60], who highlighted the misconception that correlation is evidence for agreement and suggested mean differences and LoA are needed [61], as was used in this review. We found a substantial percentage of results would be expected to have a difference >200 mL (table 2). Two clinical examples highlight important implications from the study findings (table 3).

For studies with a low risk of bias (table 2 and supplementary material), there were acceptable mean differences between the two methods, based on ATS/ERS repeatability criteria [1]. This suggests that unsupervised lung function might be useful as an outcome measure for the follow-up of groups of patients in large research studies because it is likely that the average results represent the population mean. However, the large variation and high heterogeneity reflect diverse patient demographics and different spirometry methods used across the studies.

Recently, the landscape of spirometry has changed, with new portable devices available for use by patients. Although most studies in this review were published from 2016 onwards, it is likely that future studies will experience a positive learning curve, meaning a greater number of patients will have prior experience with portable spirometers and might produce more accurate results unsupervised [41, 58]. This could also apply to the training of clinicians [53, 58]. The ARTP recommend that clinicians complete a practical examination and perform at least 50 spirometry tests on patients per year to remain competent in spirometry, and to evidence quality and consistency, highlighting the technicality of the procedures [12]. We advise relevant organisations to consider the increase in unsupervised spirometry and provide guidance on optimisation and use of home measurements. Furthermore, any new portable spirometers must be thoroughly validated, because a recent review found that only three of 10 devices from various manufacturers were technically acceptable [62].

Most studies that explored adherence reported good compliance to home spirometry. Patient satisfaction was also generally positive towards the portable spirometers and technical issues appeared to be low. However, a wide variety of methods were used to determine these outcomes. No costs were reported but these can be substantial, especially when paired with new airway clearance devices in some diseases [63].

Regarding strengths, this is the first review to comprehensively search for studies to estimate the difference between unsupervised and supervised spirometry. The large number of patients, conditions and comparisons provide strength to the meta-analysis. In the screening stage of the review, we identified several studies that reported feasibility with portable spirometers when used by patients in the presence of




FIGURE 3 Meta-analysis of Bland-Altman for forced vital capacity (FVC) (in mL) according to type of disease. LoA: limits of agreement. #: TURNER *et al.* [57] used forced expiratory volume in 6 s (FEV₆) as a surrogate for FVC.

clinicians, which is likely to influence the measurements, making it indistinguishable from a true unsupervised measurement. On this basis, such studies were not eligible for this review, and we only included studies to represent what would happen in real-world situations.

A limitation of the findings is the statistical heterogeneity in the pooled analysis and very low certainty of the evidence. Although there was significant heterogeneity in the magnitude of differences across all outcomes,

TABLE 3 Real-world clinical examples that could result from the findings of this review

Clinical scenario	Implications
A patient completes baseline FEV ₁ spirometry supervised in clinic and subsequently completes spirometry unsupervised at home and obtains the same results.	The results from this systematic review indicate that, based on the CI and LoA for FEV ₁ , a clinician cannot be confident that the results were truly the same. Despite there being no apparent change in their underlying lung function, there is the chance of a mean underestimation of 106 mL with home spirometry and a 39% chance that the difference would be >200 mL from the supervised clinic FEV ₁ measurement.
A patient who feels unwell at home records a remote FEV ₁ spirometry measurement that is >10% lower than a previous supervised clinic measurement, a change frequently used as an indicator for bronchiectasis exacerbations.	As described in the example above, this difference could be due to chance or could indicate a true decline in lung function. Crucially, if the home and clinic results appeared the same then important changes in the patient’s health could be missed, due to false reassurance to the patient and clinician.

FEV₁: forced expiratory volume in 1 s; LoA: limit of agreement; CI: confidence interval.

unsupervised measurements were consistently lower than clinic measurements in almost all studies. We were unable to create a combined Bland–Altman plot to assess patterns of variability because individual patient values were not available. Furthermore, this was a cross-sectional analysis and did not explore successive measurements. Most studies were deemed at risk due to unclear methods. Some studies did not fully report metrics around the Bland–Altman analysis. We recommend that future studies report this fully [64]. Future reviews should explore the FEV₁/FVC ratio and longitudinal analysis of data across time. As outlined in the new ERS/ATS guidelines [65], it is important we understand the reproducibility of spirometry measurements (unsupervised and supervised) and what indicates a clinically meaningful change over time. The majority of studies did not explicitly report if supervised measurements were performed under the instruction of a clinician or other trained professional. In addition, the majority of studies did not report if follow-up training on the quality of spirometry technique was performed with patients after the baseline visit to improve the quality of unsupervised measurements. The studies did not comprehensively describe how quality assessment of the spirometry was performed. Future studies should aim to provide more detail on aspects of patient training and quality assessment for both supervised and unsupervised spirometry in their methodology.

In conclusion, unsupervised home spirometry underestimates lung function measurements compared to supervised spirometry. We suggest caution and proper training if used owing to the possibility of underestimation and large variation in the differences between unsupervised and supervised measurements. Unsupervised home spirometry should not be used for diagnostic purposes; however, the results do suggest that unsupervised measurements may be suitable for outcome collection within large clinical research studies. The focus here is likely to be on the mean difference in lung function between the study groups and a large sample size could overcome the added measurement variation, and so represent the population mean. Any future research should use technically validated devices in a comprehensively trained population across multiple timepoints to fully understand the value of unsupervised home spirometry.

Points for clinical practice

It is crucial to know whether assessments, such as FEV₁ and FVC, taken by unsupervised patients are consistent with measurements taken in a clinical setting with a trained professional. Based on this review, we urge caution when using unsupervised spirometry for individual patients and suggest clinicians consider the potential for differences because measurements are not interchangeable and can result in underestimation.

Provenance: Submitted article, peer reviewed.

Acknowledgements: We thank Marlies Wijsenbeek and Karen Moor from Erasmus MC University Medical Centre in Rotterdam, the Netherlands, for providing additional data to aid the meta-analysis. We thank Kate Hayes from Queen's University Belfast for insight on qualitative analysis. We also thank Richard Fallis from Queen's University Belfast for expertise on the search strategy.

Data sharing: Study data are available on request from the corresponding author.

Author contributions: R. Anand: conceptualisation, methodology, searching, screening, full-text review, extraction, formal analysis, data curation, project administration, visualisation, validation, writing original draft, and manuscript review and editing. R. McLeese: methodology, screening, full-text review, extraction, interpretation, validation, and manuscript review and editing. J. Busby: methodology, screening, full-text review, extraction, statistical analysis, data curation, visualisation, and manuscript review and editing. J. Stewart: methodology, searching, screening, full-text review, extraction, interpretation, visualisation, and manuscript review and editing. M. Clarke: conceptualisation, methodology, screening, full-text review, interpretation, and manuscript review and editing. W.D-C. Man: interpretation, and manuscript review and editing. J. Bradley: conceptualisation, methodology, searching, screening, full-text review, extraction, funding acquisition, project administration, and manuscript review and editing. All authors had full access to all the data and agreed with the final decision to submit for publication. R. Anand and J. Busby accessed and verified the data.

Conflict of interest: R. Anand, M. Clarke and J. Bradley declare that they are investigators on an ongoing clinical trial investigating bronchiectasis in which patients complete home and clinic spirometry that is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme and supported by PARI Pharma; outside the submitted work. J. Busby has received personal fees from NuvoAir for advisory board attendance, outside the submitted work. W.D-C. Man is part-funded by a NIHR Artificial Intelligence Award exploring the use of artificial intelligence software in the interpretation of primary care spirometry and is Honorary President of the Association of Respiratory Physiology and Technology (ARTP), outside the submitted work. All other authors have nothing to disclose.

References

- 1 Graham BL, Steenbruggen I, Miller MR, *et al.* Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med* 2019; 200: e70–e88.
- 2 Moore VC. Spirometry: step by step. *Breathe* 2012; 8: 232–240.
- 3 Halpin DMG, Criner GJ, Papi A, *et al.* Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2021; 203: 24–36.
- 4 Løpönen J, Ilmarinen P, Tuomisto LE, *et al.* Daily physical activity and lung function decline in adult-onset asthma: a 12-year follow-up study. *Eur Clin Respir J* 2018; 5: 1533753.
- 5 Pasteur MC, Bilton D, Hill AT, *et al.* British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010; 65: Suppl. 1, i1–i58.
- 6 VanDevanter DR, Konstan MW. Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. *Clin Investig (Lond)* 2012; 2: 163–175.
- 7 Carpenter DM, Jurdi R, Roberts CA, *et al.* A review of portable electronic spirometers: implications for asthma self-management. *Curr Allergy Asthma Rep* 2018; 18: 53.
- 8 Liu XL, Tan JY, Wang T, *et al.* Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. *Rehabil Nurs* 2014; 39: 36–59.
- 9 Mathioudakis AG, Abroug F, Agusti A, *et al.* ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. *Eur Respir J* 2022; 59: 2102006.
- 10 Spargo M, Ryan C, Downey D, *et al.* Development of a core outcome set for trials investigating the long-term management of bronchiectasis. *Chron Respir Dis* 2019; 16: 1479972318804167.
- 11 Gilchrist FJ, Ali I, Brodli M, *et al.* Developing a core outcome set for children with protracted bacterial bronchitis. *ERJ Open Res* 2020; 6: 00344–2019.
- 12 Cooper BG, Hull JH, Lloyd JK. ARTP statement on pulmonary function testing. *BMJ Open Resp Res* 2020; 7: e000664.
- 13 Quer G, Radin JM, Gadaleta M, *et al.* Wearable sensor data and self-reported symptoms for COVID-19 detection. *Nat Med* 2021; 27: 73–77.
- 14 Hartman D, Heaton P, Cammack N, *et al.* Clinical trials in the pandemic age: what is fit for purpose? *Gates Open Res* 2020; 4: 58.
- 15 Mantena S, Keshavjee S. Strengthening healthcare delivery with remote patient monitoring in the time of COVID-19. *BMJ Health Care Inform* 2021; 28: e100302.
- 16 Madge S. Remote Monitoring and Virtual Clinic for Patients with Respiratory Conditions. NHS England – Transformation Directorate, 2021. www.nhs.uk/key-tools-and-info/digital-playbooks/respiratory-digital-playbook/remote-monitoring-and-virtual-clinic-for-patients-with-respiratory-conditions/ Date last accessed: 1 August 2022.
- 17 CF Foundation. Over 10,000 Home Spirometers Provided for Virtual Care Visits Through CF Foundation Program. 2020. www.cff.org/node/691 Date last accessed: 1 August 2022. Date last updated: 27 August 2020.
- 18 NHS England. Thousands of Patients to Benefit from NHS At Home Roll-out 2020. www.england.nhs.uk/2020/06/thousands-of-patients-to-benefit-from-nhs-at-home-roll-out/ Date last accessed: 1 August 2022. Date last updated: 5 June 2020.
- 19 Finkelstein J, Cabrera MR, Hripcsak G. Internet-based home asthma telemonitoring: can patients handle the technology? *Chest* 2000; 117: 148–155.
- 20 Edwards C, Costello E, Cassidy N, *et al.* Use of the patientMpower APP with home-based spirometry to monitor the symptoms and impact of fibrotic lung conditions: longitudinal observational study. *JMIR Mhealth Uhealth* 2020; 8: e16158.
- 21 Jaana M, Paré G, Sicotte C. Home telemonitoring for respiratory conditions: a systematic review. *Am J Manag Care* 2009; 15: 313–320.
- 22 Baroi S, McNamara RJ, McKenzie DK, *et al.* Advances in remote respiratory assessments for people with chronic obstructive pulmonary disease: a systematic review. *Telemed J E Health* 2018; 24: 415–424.
- 23 NICE. COVID-19 rapid guideline: severe asthma. NG166. London, National Institute for Health and Care Excellence (NICE), 2020. www.ncbi.nlm.nih.gov/pubmed/33497152 Date last accessed: 1 August 2022.
- 24 Sheikh A, Anderson M, Albala S, *et al.* Health information technology and digital innovation for national learning health and care systems. *Lancet Digit Health* 2021; 3: e383–e396.
- 25 Clarke M. Guide to the Contents of a Cochrane Methodology Protocol and Review. 2020. https://methodology.cochrane.org/sites/methodology.cochrane.org/files/uploads/guide_to_the_contents_of_a_cochrane_methodology_protocol_and_review.pdf
- 26 Anand R, McLeese R, Stewart J, *et al.* Unsupervised remote spirometry vs supervised clinic spirometry: a protocol for a systematic review. PROSPERO, 2021. www.crd.york.ac.uk/prospero/display_record.php?RecordID=272816

- 27 Higgins LT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. *In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions, v6.3. The Cochrane Collaboration, 2022. www.training.cochrane.org/handbook*
- 28 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539–1558.
- 29 Deeks JJ, Higgins JPT, Altman DG, et al. Chapter 10: Analysing data and undertaking meta-analyses. *In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions, 2nd ed. The Cochrane Collaboration, 2019; pp. 241–284.*
- 30 Gerzon FLGR, Jöbsis Q, Bannier MAGE, et al. Discrepancy between lung function measurements at home and in the hospital in children with asthma and CF. *J Clin Med* 2020; 9: 1617.
- 31 Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011; 155: 529–536.
- 32 Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. *J Clin Epidemiol* 2020; 122: 129–141.
- 33 Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. *J Clin Epidemiol* 2020; 122: 142–152.
- 34 Bell JM, Sivam S, Dentice RL, et al. Quality of home spirometry performance amongst adults with cystic fibrosis. *J Cyst Fibros* 2022; 21: 84–87.
- 35 Broos CE, Wapenaar M, Looman CWN, et al. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. *Eur Respir J* 2018; 51: 1702089.
- 36 Cheng G-S, Campbell AP, Xie H, et al. Correlation and agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant* 2016; 22: 925–931.
- 37 Edmondson C, Westrupp N, Wallenburg J, et al. What is feasible when it comes to monitoring young people with cystic fibrosis at home? The results of the CLIMB CF study. *Pediatr Pulmonol* 2020; 55: Suppl. 2, 297.
- 38 Finkelstein SM, Lindgren B, Prasad B, et al. Reliability and validity of spirometry measurements in a paperless home monitoring diary program for lung transplantation. *Heart Lung* 1993; 22: 523–533.
- 39 Huang C, Izmailova ES, Jackson N, et al. Remote FEV₁ monitoring in asthma patients: a pilot study. *Clin Transl Sci* 2021; 14: 529–535.
- 40 Kerwin EM, Hickey L, Small CJ. Relationship between handheld and clinic-based spirometry measurements in asthma patients receiving beclomethasone. *Respir Med* 2019; 151: 35–42.
- 41 Khan F, Howard L, Hearson G, et al. Clinical utility of home versus hospital spirometry in fibrotic interstitial lung disease: evaluation after INJUSTIS interim analysis. *Ann Am Thorac Soc* 2022; 19: 506–509.
- 42 Lindgren BR, Finkelstein SM, Prasad B, et al. Determination of reliability and validity in home monitoring data of pulmonary function tests following lung transplantation. *Res Nurs Health* 1997; 20: 539–550.
- 43 Marcoux V, Wang M, Burgoyne SJ, et al. Mobile health monitoring in patients with idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2019; 16: 1327–1329.
- 44 Moor CC, Wapenaar M, Miedema JR, et al. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. *Respir Res* 2018; 19: 105.
- 45 Moor CC, Gür-Demirel Y, Wijsenbeek MS. Feasibility of a comprehensive home monitoring program for sarcoidosis. *J Pers Med* 2019; 9: 23.
- 46 Moor CC, Mostard RLM, Grutters JC, et al. Home monitoring in patients with idiopathic pulmonary fibrosis. A randomized controlled trial. *Am J Respir Crit Care Med* 2020; 202: 393–401.
- 47 Moor CC, van den Berg CAL, Visser LS, et al. Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. *ERJ Open Res* 2020; 6: 00054–2020.
- 48 Moor CC, van Leuven SI, Wijsenbeek MS, et al. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. *Rheumatology (Oxford)* 2021; 60: 2467–2471.
- 49 Morlion B, Knoop C, Paiva M, et al. Internet-based home monitoring of pulmonary function after lung transplantation. *Am J Respir Crit Care Med* 2002; 165: 694–697.
- 50 Mortimer KM, Fallot A, Balmes JR, et al. Evaluating the use of a portable spirometer in a study of pediatric asthma. *Chest* 2003; 123: 1899–1907.
- 51 Odisho A, Singer JP, Perez A, et al. Implementation of a chatbot mobile health intervention with home spirometry to monitor lung transplant recipients remotely. *J Heart Lung Transplant* 2021; 40: S146.
- 52 Paynter A, Khan U, Heltshe SL, et al. A comparison of clinic and home spirometry as longitudinal outcomes in cystic fibrosis. *J Cyst Fibros* 2022; 21: 78–83.
- 53 Rodriguez-Roisin R, Tetzlaff K, Watz H, et al. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 1973–1981.
- 54 Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 194: 989–997.

- 55 Shakkottai A, Kaciroti N, Kasmikha L, *et al.* Impact of home spirometry on medication adherence among adolescents with cystic fibrosis. *Pediatr Pulmonol* 2018; 53: 431–436.
- 56 Sheshadri A, Alousi A, Bashoura L, *et al.* Feasibility and reliability of home-based spirometry telemonitoring in allogeneic hematopoietic cell transplant recipients. *Ann Am Thorac Soc* 2020; 17: 1329–1333.
- 57 Turner J, He Q, Baker K, *et al.* Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. *Transplant Cell Ther* 2021; 27: 616.
- 58 Veit T, Barnikel M, Crispin A, *et al.* Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. *Respir Res* 2020; 21: 270.
- 59 Wijbenga N, Hoek RAS, Mathot BJ, *et al.* Evaluation of a home monitoring application for follow up after lung transplantation—a pilot study. *J Pers Med* 2020; 10: 240.
- 60 Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986; 327: 307–310.
- 61 Bunce C. Correlation, agreement, and Bland–Altman analysis: statistical analysis of method comparison studies. *Am J Ophthalmol* 2009; 148: 4–6.
- 62 Wu Z, Huang R, Zhong L, *et al.* Technical performance analysis of different types of spirometers. *BMC Pulm Med* 2022; 22: 23.
- 63 Delestre-Levai I, Aliberti S, Almagro M, *et al.* Patients' perspectives on bronchiectasis: findings from a social media listening study. *ERJ Open Res* 2021; 7: 00096-2021.
- 64 Abu-Arafeh A, Jordan H, Drummond G. Reporting of method comparison studies: a review of advice, an assessment of current practice, and specific suggestions for future reports. *Br J Anaesth* 2016; 117: 569–575.
- 65 Stanojevic S, Kaminsky DA, Miller MR, *et al.* ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 2022; 60: 2101499.